TERT and urinary bladder cancer: Beyond TERT mutations, ADGRG6 enhancer hotspot mutations manifest at a substantial rate (50%) in bladder cancer and offer diagnostic sensitivity and specificity of 83.3% and 98.4%, respectively, suggesting their utility in early screening and monitoring (Tan et al., 2023).